InvestorsHub Logo
Followers 839
Posts 120523
Boards Moderated 18
Alias Born 09/05/2002

Re: None

Friday, 08/12/2022 11:07:42 AM

Friday, August 12, 2022 11:07:42 AM

Post# of 6482
Prevnar-20 hits_primary_endpoints_in phase-3 trial_in infants:

https://www.businesswire.com/news/home/20220812005073/en

The Prevnar franchise is PFE’s biggest seller not related to COVID. In the adult segment of the market, Prevnar-20 has achieved a 97% market share with MRK’s Vaxneuvance a very distant #2 (#msg-169520866, #msg-166441188).

The pediatric segment of the pneumococcal-vaccine market figures to be more competitive since MRK’s Vaxneuvance has a head start from its FDA approval in Jun 2022 (#msg-169208458).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PFE News